A large number of men aging >40 years seek physician’s advice because of abnormal blood levels of prostate specific antigen (PSA) and/or voiding symptoms. In routine clinical practice, their evaluation includes palpation of the prostate through the rectum (DRE) to determine whether it feels benign or contains areas of greater consistence thus suspicious for being cancer. Men with an abnormal PSA value and/or a suspicious DRE are scheduled for prostate biopsy to determine whether such findings are due to a benign condition or to the presence of Prostate Cancer.
By doing so, prostate biopsy will find Prostate Cancer in approximately 40% of cases and this number drops to 25% in men with PSA values below 10ng/ml. Therefore, great effort has been made to identify other clinical parameters that may predict the outcome of prostate biopsy and to combine them with PSA levels and DRE findings into sophisticated statistical models that allow to calculate the risk of being diagnosed with Prostate Cancer.
The Foggia Prostate Cancer Risk Calculator is based on a population of Caucasian men who underwent an extended (18-core) prostate biopsy. It includes clinical parameters commonly obtained in men seeking medical advice because of abnormal PSA and/or voiding symptoms, such as age, prostate volume and post-void residual urine volume.
The model does not include, i.e. THE CALCULATOR DOES NOT APPLY TO:
- men having already undergone prostate biopsy;
- men with PSA >20ng/ml, due to their high risk of being diagnosed with Prostate Cancer;
- men with factors affecting PSA values (treatment with 5-α reductase inhibitors or previous prostate surgery);
- men with an indwelling urethral catheter, as post-void residual urine volume could not be measured